65,437 trials
Typhoid Fever
Primary: Percentage of Subjects With at Least 4-fold Increase in Anti-Vi Enzyme-linked Immunosorbent Assay (ELISA) Titer — 100; 85; 100; 89 percentage of subjects
Pulmonary Disease, Chronic Obstructive
Primary: Trough FEV1 After 12 Weeks on Study Drug — 0.0378; 0.0947 Litre — p=0.3025
Prostate Cancer
Primary: Number of Participants With a Pathology Tumor Stage of Less Than or Equal to Prostate Cancer Stage at Which the Tumor is Confined to the Prostate (pT2) — 24; 8…
Alopecia · Baldness
Primary: Change From Baseline in Target Area Hair Count (TAHC) — 153.1; 161.1; 145.2; 163.0 terminal hairs/cm^2
Cancer of Head and Neck
Primary: The Primary Endpoint is the Local Regional Control Rate Assessed 3 Months Post Completion of Radiation Therapy. — 43 participants
Multiple Sclerosis
Primary: MRI Parameter- Percent Brain Volume Change for 2 Years — -0.862; -0.49 percent change per year
Schizophrenia, Undifferentiated Type
Primary: Identification of Brain Circuits Involved in a Task of Emotional Congruence (With fMRI) — -0.25; -0.21; 3.8; 0.2 arbitrary units of activation
Breast Cancer
Primary: Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease That Lasts More Than 6 Months) — 36 percentage of patients
Gastrointestinal Neoplasms · Ovarian Neoplasms
Primary: Overall Response — 3 participants
Smith-Lemli-Opitz Syndrome
Primary: Hyperactivity Sub-scale of the Aberrant Behavior Checklist-Community (ABC-C). — 8.6; 8.6 units on a scale — p=1.0
Bone Metastases
Primary: Time to the First On-Study Skeletal-Related Event (Non-Inferiority) — 496.0; 625.0 Days — p=0.0007
Asthma
Primary: Methacholine Challenge (MCC) Results — 14; 36 participants
Menstrual Migraine
Primary: Migraine Recurrence — 0; 2 participants
Diabetes
Primary: Percent of Blood Glucose Results Within +/-15 mg/dL(<75 mg/dL) and Within +/-20% (>=75 mg/dL) of the Reference Instrument BG Value — 100.0; 99.5; 99.5 percentage of…
Coronary Artery Disease
Primary: Delta Cardiac Troponin I (ΔcTnI) — 0.04; 0.19 ng/mL